×

Research and Markets: Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/mnf4v3/competitor) has announced the addition of the "Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors" report to their offering.

The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 on B-cells used to treat B-cell mediated malignancies and rheumatoid arthritis as of October 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Genentech/Roche is one of the world's commercially most successful antibodies (2011 sales of over US$ 6.4 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies.

The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies (mabs) with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already in phase III.

The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,

- Target / Mechanism of Action,

- Class of Compound,

- Company,

- Product Category,

- Indication,

- R&D Stage and

- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Key Topics Covered:

- Marketed CD20 Antibodies

- Biobetter/Biosuperior Antibodies

- Bispecific CD20 Antibodies

- Rituximab Biosimilars

- Corporate CD20 Antibody R&D Pipelines

- About La Merie

For more information, including list of companies mentioned, please visit http://www.researchandmarkets.com/research/mnf4v3/competitor

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source: Research and Markets